Retrospective 176 hospitalized patients, 96 treated with oral vitamin C (from 500mg to 1500mg daily), showing lower mortality with treatment.
Although the 29% lower mortality is not statistically significant, it is consistent with the significant 20% lower mortality
[10‑28%] from meta analysis of the
46 mortality results to date.
, which show efficacy with
p=0.0012.
Standard of Care (SOC) for COVID-19 in the study country,
the USA, is
very poor with
very low average efficacy for approved treatments
1.
Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
This may explain in part the very high mortality seen in this study.
Results may differ in countries with improved SOC.
|
risk of death, 29.5% lower, RR 0.71, p = 0.18, treatment 22 of 96 (22.9%), control 26 of 80 (32.5%), NNT 10.
|
|
risk of death, 15.6% lower, RR 0.84, p = 0.60, treatment 15 of 30 (50.0%), control 16 of 27 (59.3%), NNT 11, ICU patients.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Patel et al., 1 Oct 2020, retrospective, USA, peer-reviewed, 8 authors, dosage 1000mg days 1-4, 500mg to 1500mg daily.
THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19
Manishkumar Patel, Gloria Hong, Bernadette Schmidt, Laith Al-Janabi, Radha Kishan Adusumilli, Jurgena Tusha, Padmini Giri, Sarwan Kumar
Chest, doi:10.1016/j.chest.2020.08.322
Our observational study showed even when ascorbic acid is administered in oral form as an adjunct to COVID-19 therapy, it is associated with a mortality benefit and improved extubation rate. DISCLOSURES: No relevant relationships by Radha Kishan Adusumilli, source¼Web Response No relevant relationships by Laith Al-janabi, source¼Web Response No relevant relationships by Padmini Giri, source¼Web Response No relevant relationships by Gloria Hong, source¼Web Response No relevant relationships by Sarwan Kumar, source¼Web Response No relevant relationships by Manishkumar Patel, source¼Web Response No relevant relationships by Bernadette Schmidt, source¼Web Response No relevant relationships by Jurgena Tusha, source¼Web Response
DOI record:
{
"DOI": "10.1016/j.chest.2020.08.322",
"ISSN": [
"0012-3692"
],
"URL": "http://dx.doi.org/10.1016/j.chest.2020.08.322",
"alternative-id": [
"S0012369220325083"
],
"author": [
{
"affiliation": [],
"family": "Patel",
"given": "Manishkumar",
"sequence": "first"
},
{
"affiliation": [],
"family": "Hong",
"given": "Gloria",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Schmidt",
"given": "Bernadette",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Al-janabi",
"given": "Laith",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Adusumilli",
"given": "Radha Kishan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tusha",
"given": "Jurgena",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Giri",
"given": "Padmini",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kumar",
"given": "Sarwan",
"sequence": "additional"
}
],
"container-title": "Chest",
"container-title-short": "Chest",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
10,
12
]
],
"date-time": "2020-10-12T10:45:50Z",
"timestamp": 1602499550000
},
"deposited": {
"date-parts": [
[
2020,
12,
2
]
],
"date-time": "2020-12-02T15:14:58Z",
"timestamp": 1606922098000
},
"indexed": {
"date-parts": [
[
2024,
3,
19
]
],
"date-time": "2024-03-19T07:16:51Z",
"timestamp": 1710832611348
},
"is-referenced-by-count": 5,
"issue": "4",
"issued": {
"date-parts": [
[
2020,
10
]
]
},
"journal-issue": {
"issue": "4",
"published-print": {
"date-parts": [
[
2020,
10
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
10,
1
]
],
"date-time": "2020-10-01T00:00:00Z",
"timestamp": 1601510400000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0012369220325083?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0012369220325083?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "A325",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
10
]
]
},
"published-print": {
"date-parts": [
[
2020,
10
]
]
},
"publisher": "Elsevier BV",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0012369220325083"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Cardiology and Cardiovascular Medicine",
"Critical Care and Intensive Care Medicine",
"Pulmonary and Respiratory Medicine"
],
"subtitle": [],
"title": "THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19",
"type": "journal-article",
"volume": "158"
}
